News

SSP concludes Neuraxpharm acquisition of Swiss-based S.T.U. GmbH - CBD brand Hemplix™

Langenfeld, Germany, 4. January 2020 Neuraxpharm Group (Neuraxpharm), a leading European specialty pharmaceutical company focused on the central nervous system (CNS), announced the acquisition of S.T.U. GmbH (Swiss Trade Union or S.T.U.), a leading Switzerland-based developer and distributor of natural cannabidiol (CBD) consumer products. The deal enables Neuraxpharm to enter the fast-growing CBD space and to build on its business of CNS-related products, including value-added medicines, standard generics and consumer healthcare products. The acquisition is in line with Neuraxpharm's strategy to expand its presence in Europe entering a key market. Switzerland is now the 10th European market

Featured Posts
Recent Posts
Archive
Follow Us

Strategic Swiss Partners AG,

Bahnhofstrasse 10 / Börsenstrasse 18, 8001 Zürich  SWITZERLAND

info@strategicswisspartners.com  |   +41 44 980 8000 

Copyright   ©   Strategic Swiss Partners AG 2019